Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 18 of 18

List	Outcome	Time frame	Description
Primary	Waist Circumference (WC)	12 weeks.	WC was measured with a flexible tape at the midline between the highest point of the iliac crest and the lowest rib in the midaxillary line.
Primary	Fasting Serum Glucose	12 weeks.	Fasting serum glucose concentration was measured with enzymatic/colorimetric techniques by spectrophotometry.
Primary	Triglycerides (TG)	12 weeks.	TG concentration was measured with enzymatic/colorimetric techniques by spectrophotometry.
Primary	High-Density Lipoprotein (HDL-C)	12 weeks.	Serum HDL-C concentration was measured with enzymatic/colorimetric techniques by spectrophotometry.
Primary	Systolic Blood Pressure	12 weeks.	Blood pressure was evaluated using a digital sphygmomanometer after a resting period of 15 min with the subject sitting; the bracelet was adjusted 3.0 cm above the fold of the elbow of the left arm.
Primary	Diastolic Blood Pressure	12 weeks.	Blood pressure was evaluated using a digital sphygmomanometer after a resting period of 15 min with the subject sitting; the bracelet was adjusted 3.0 cm above the fold of the elbow of the left arm.
Primary	Matsuda-DeFronzo Insulin Sensitivity Index	12 weeks.	The Matsuda-DeFronzo index measures whole-body insulin sensitivity from serum insulin and glucose levels during an oral glucose tolerance test (OGTT). The index is calculated with the formula: 10,000 / sqrt(\[fasting glucose (mg/dL) × fasting insulin (µU/mL)\] × \[mean glucose × mean insulin during OGTT\]). The scale ranges from 0 to infinity, with higher values indicating greater insulin sensitivity. Typical values for healthy individuals range between 2 and 10, while lower values suggest insulin resistance.
Primary	Total Insulin Secretion	12 weeks.	The Total Insulin Secretion is calculated as the ratio of the area under the curve (AUC) for insulin to the AUC for glucose during a 120-minute oral glucose tolerance test (OGTT). The formula is: AUC insulin / AUC glucose. AUC values are derived from concentrations measured at 0, 30, 60, 90, and 120 minutes post-ingestion of a glucose solution at week 12. Interpretation of the AUC insulin/AUC glucose ratio is as follows: values \<0.5 indicate insulin resistance, values between 0.5 and 1.0 suggest moderate insulin secretion, and values \>1.0 reflect optimal insulin secretion.
Primary	Stumvoll Index	12 weeks.	The Stumvoll index measures the first phase of insulin secretion, incorporates demographic data along with plasma glucose (mmol/L) and insulin (pmol/L) levels measured during an oral glucose tolerance test (OGTT). There is no universally standardized ranges, values ranges from 0 to infinity; higher values indicate a better early insulin response to glucose (first 30 minutes), reflecting more effective beta-cell function.
Secondary	Body Weight	12 weeks.	Body weight was measured at baseline a bioimpedance scale.
Secondary	Body Mass Index (BMI)	12 weeks.	BMI was calculated with the Quetelet index formula.
Secondary	Body Fat	12 weeks.	Percentage of body fat was measured using a bioimpedance scale.
Secondary	Total Cholesterol (TC)	12 weeks.	Serum Total Cholesterol concentration was measured with enzymatic/colorimetric techniques by spectrophotometry.
Secondary	Low-Density Lipoprotein (LDL-C)	12 weeks.	Serum LDL-C concentration was calculated using the Friedewald formula (LDL-C = TC - (HDL-C + \[TG/5\])
Secondary	Very-Low-Density Lipoprotein (VLDL)	12 weeks.	Serum VLDL concentration was calculated with the formula: VLDL-C = TG/5.
Secondary	Alanine Aminotransferase (ALT)	12 weeks.	Serum ALT concentration was measured with enzymatic/colorimetric techniques by spectrophotometry.
Secondary	Aspartate Aminotransferase (AST)	12 weeks.	Serum AST concentration was measured with enzymatic/colorimetric techniques by spectrophotometry.
Secondary	Creatinin	12 weeks.	Serum creatinin concentration was measured with enzymatic/colorimetric techniques by spectrophotometry.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03613740/registered

API reference For AI assistants